Abstract
Background The Measles-Mumps-Rubella vaccine is given as a two-dose course in childhood, but the schedule of the second dose varies between countries. England recommended bringing forward the second dose from three years and four months to 18 months by 2025. We aim to quantify how changing the vaccine schedule could impact measles transmission dynamics.
Methods We used a mathematical model stratified by age group and region to generate stochastic outbreaks with different vaccine schedules. We used detailed information on vaccine uptake for different age groups by region and year from electronic health records and modelled alternative scenarios changing the timing of the second MMR dose or changing uptake of either dose. We simulated measles incidence between 2010 and 2019 and compared the number of cases in each scenario.
Results and discussion Delivering the second MMR vaccine at younger age resulted in a lower number of cases than in the reference set of simulations with 16% (IQR: 1.93– 28.48%) cases averted when the second dose was given at 18 months. The number of cases decreased even if the coverage of the second dose decreased by up to 3% (median reduction 15.94%; IQR: 0.41 −28.21%). The impact on case numbers was equivalent to increasing first dose coverage by 0.5% every year between 2010 and 2019 (16.38 % reduction, IQR:1.90 - 28.45), more cases could be avoided (28.60%, IQR: 17.08 - 38.05) if the first dose coverage was increased by 1% every year.
Our data highlighted how patterns of vaccination uptake translate into outbreak risk. Although increasing coverage of the first MMR dose led to the best results, this may be challenging to achieve requiring substantial resources with already high coverage of the first dose. Hence, an earlier second MMR dose presents a good alternative for mitigating the risk of measles outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AS and HM are funded by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation (NIHR200929), a partnership between UK Health Security Agency and the London School of Hygiene and Tropical Medicine. The views expressed are those of the author(s) and not necessarily those of the NIHR, UK Health Security Agency or the Department of Health and Social Care. CWG is supported by a Wellcome Career Development Award (225868/Z/22/Z). AR was supported by the National Institute for Health Research (NIHR200908), AJK was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (206250/Z/17/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We received data governance approval from Clinical Practice Research Link (protocol number 22_001706) and ethical approval from the London School of Hygiene and Tropical Medicine research ethics committee (reference number 27651).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
The study uses data from the Clinical Practice Research Datalink (CPRD). CPRD does not allow the sharing of patient-level data. The data specification for the CPRD data set is available at: https://cprd.com/cprd-aurum-may-2022-dataset. The COVER data is publicly available: https://www.england.nhs.uk/statistics/statistical-work-areas/child-immunisation/.
The analysis code can be found in the following GitHub repository: https://github.com/alxsrobert/measles_england_sir/tree/vaccination_scenarios/R
